Best Pharma & Healthcare Funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 19 direct-growth funds ranked by a transparent 0–100 Smart Score
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 81 | Strong Buy | 20.9% | 24.3% | 18.5% | 1.27 | 1.97 | 14.4 | 5.3 | 0.83 | — | 58.4 | 1.04% | ₹5.8k Cr | 13.7y | |
| HDFC Pharma And Healthcare HDFC | 81 | Strong Buy | 27.3% | — | — | 1.84 | 2.64 | 14.0 | 21.9 | 0.66 | — | 50.4 | 1.08% | ₹3.3k Cr | 3.0y | |
| Kotak Healthcare Kotak | 68 | Buy | 27.3% | — | — | 1.19 | 1.69 | 14.4 | 15.7 | 0.68 | — | 50.9 | 1.09% | ₹768 Cr | 2.8y | |
| UTI Healthcare UTI | 65 | Buy | 16.8% | 24.1% | 16.1% | 1.17 | 1.87 | 16.0 | 4.7 | 0.90 | — | 42.6 | 1.26% | ₹1.4k Cr | 13.7y | |
| Mirae Asset Healthcare Mirae Asset | 60 | Hold | 19.6% | 23.0% | 15.9% | 1.10 | 1.66 | 16.2 | 3.1 | 0.94 | — | 48.2 | 0.61% | ₹3.6k Cr | 8.3y | |
| DSP Healthcare DSP | 58 | Hold | 16.5% | 21.8% | 15.5% | 1.11 | 1.68 | 14.9 | 4.3 | 0.79 | — | 37.5 | 0.73% | ₹3.8k Cr | 7.8y | |
| ICICI Pru Healthcare ICICI Pru | 51 | Hold | 5.9% | 22.0% | 16.1% | 1.09 | — | 16.2 | 3.4 | 0.91 | — | — | 1.31% | ₹7.0k Cr | 8.2y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 51 | Hold | 22.3% | — | — | — | — | — | — | — | — | 53.0 | 1.13% | ₹902 Cr | 2.6y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 24.4% | — | — | 0.56 | 0.76 | 13.1 | 11.1 | 0.66 | — | 54.6 | 0.93% | ₹125 Cr | 1.8y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 47 | Hold | 21.2% | — | — | 0.41 | 0.56 | 13.4 | 7.7 | 0.68 | — | 51.4 | 0.90% | ₹406 Cr | 1.7y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 44 | Avoid | 17.6% | 21.5% | 14.4% | 1.10 | 1.69 | 15.3 | 2.8 | 0.90 | — | 50.4 | 1.02% | ₹1.1k Cr | 7.2y | |
| Tata India Pharma & Healthcare Tata | 44 | Avoid | 9.2% | 19.8% | 14.7% | 1.01 | 1.43 | 13.2 | 10.3 | 0.63 | — | 43.9 | 1.00% | ₹1.6k Cr | 10.7y | |
| Nippon India Pharma Nippon India | 40 | Avoid | 10.6% | 18.6% | 13.8% | 0.93 | 1.33 | 13.0 | 9.3 | 0.59 | — | 39.8 | 0.99% | ₹9.5k Cr | 13.7y | |
| LIC MF Healthcare LIC | 37 | Avoid | 15.8% | 22.5% | 12.8% | 1.12 | 1.62 | 15.9 | 4.1 | 0.88 | — | 53.2 | 1.42% | ₹103 Cr | 7.6y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 33 | Avoid | 11.4% | — | — | 0.15 | 0.22 | 11.4 | 6.0 | 0.57 | — | 45.7 | 1.56% | ₹507 Cr | 1.3y | |
| ITI Pharma And Healthcare ITI | 29 | Avoid | 12.4% | 20.2% | — | 0.94 | 1.35 | 16.4 | 0.8 | 0.94 | — | 48.5 | 0.92% | ₹276 Cr | 4.9y | |
| Bandhan Healthcare Bandhan | 27 | Avoid | — | — | — | — | — | — | — | — | — | 41.2 | 1.22% | ₹332 Cr | 0.9y | |
| Quant Healthcare Quant | 23 | Avoid | 18.1% | 20.9% | — | 0.92 | 1.15 | 18.2 | 2.8 | 0.89 | — | 33.9 | 1.49% | ₹428 Cr | 3.2y | |
| Invesco India Pharma and Healthcare Invesco | 3 | Avoid | — | — | — | — | — | — | — | — | — | — | — | ₹0 Cr | 0.0y |
Pharma & Healthcare funds — quick answers
›Which is the best Pharma & Healthcare mutual fund right now?
SBI Healthcare Opportunities currently ranks #1 of 19 Pharma & Healthcare funds with a FundLens Smart Score of 81/100 (Strong Buy). It returned 24.3% over 3 years and 18.5% over 5 years at a 1.04% expense ratio (direct plan). Rankings are recomputed from data updated 20 Sept 2026.
›Which Pharma & Healthcare fund has the best risk-adjusted returns?
HDFC Pharma And Healthcare leads the category on the Sortino ratio at 2.64 (Sharpe 1.84) — meaning it has delivered the most return per unit of downside risk among Pharma & Healthcare funds.
›Which Pharma & Healthcare fund has the lowest expense ratio?
Mirae Asset Healthcare charges 0.61% a year (direct plan) — the lowest in the category. Lower fees compound in your favour over long holding periods.
›Which is the smallest Pharma & Healthcare fund by AUM?
Invesco India Pharma and Healthcare manages ₹0 Cr, the smallest in the category. Smaller funds can be nimbler, but check track record and costs before treating size alone as an edge.
›How long should I stay invested in a Pharma & Healthcare fund?
Pharma & Healthcare funds carry very high risk, so a horizon of 7+ years is generally sensible. Defensive-growth exposure to pharma, hospitals and diagnostics. This is research, not investment advice.
Want these answers conversationally? Ask FundLens · New to the ratios? Sharpe vs Sortino, explained